Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143039 · ClinicalTrials.gov registry record
Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR
A clinical trial, sponsored by Obstetrix Medical Group.
- Terminated
- Registry status
- 48
- Enrollment target
NCT00143039 is a clinical trial that was terminated before completion, run by Obstetrix Medical Group. The registered enrollment target is 48 participants.
The verdict
NCT00143039 was terminated before completion, sponsored by Obstetrix Medical Group.
- TERMINATED
- Registry status
- 48 participants
- Enrollment target
Study Summary
The objective of this pilot study is to prospectively evaluate amniotic fluid of pregnancies complicated by non-immune hydrops and severe symmetrical intrauterine growth restriction by tandem mass spectrometry for inborn errors of metabolism.
Interventions
- PROCEDURE Tandem MS test for inborn errors of metabolism
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143039
The ClinicalTrials.gov registry entry for NCT00143039 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Obstetrix Medical Group, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tandem MS test for inborn errors of metabolism is the first listed.
NCT00143039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143039 about?
NCT00143039 is a clinical study titled "Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR". The objective of this pilot study is to prospectively evaluate amniotic fluid of pregnancies complicated by non-immune hydrops and severe symmetrical intrauterine growth restriction by tandem mass spectrometry for inborn errors of metabolism.
What is the current status of trial NCT00143039?
This trial is currently terminated. The enrollment target is 48 participants. The study started on 2006-03. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00143039?
The interventions under investigation include: Tandem MS test for inborn errors of metabolism (PROCEDURE).
Who is sponsoring clinical trial NCT00143039?
This trial is sponsored by Obstetrix Medical Group, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.